Britain and America have announced a important trade agreement that will guarantee zero levies on UK pharmaceutical products being sold in the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to increase funding on pharmaceuticals through the public health system. This pledge ensures that import taxes on these crucial goods will stay at zero for a period of 36 months.
This development follows earlier statements to significantly raise duties on branded drug imports, with figures floated reaching one hundred percent.
"This agreement with the United Kingdom reinforces the global environment for new treatments and establishes much-needed fairness to U.S.–U.K. medicine commerce," a statement said.
Economic Importance
Drugs represent one of the the United Kingdom's largest export categories to the US, which is clearly the biggest destination for major companies like GSK and AstraZeneca.
Trade data show that in the one-year period to the end of the third quarter, the UK exported drugs worth billions to the US. This value represented 17.4% of total UK exports in that timeframe.
"This agreement safeguards employment, boosts funding and facilitates the UK to become a worldwide center for medical research," a government official stated.
Specific UK Commitments
The deal involves several notable changes from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a target to double overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must pay back to the NHS to prevent overspending will be capped at fifteen percent. In the past, rebates exceeded 20%.
Industry Background
This agreement takes place against a protracted dispute between the drug companies and the UK government over spending levels and NHS adoption.
This friction were heightened by assertions that US customers were charged a premium for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been paused or abandoned, while major investments have been directed toward projects in the United States.
One official publicly accepted that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had shrunk as a percentage of its total funding over the past decade.
